<DOC>
	<DOCNO>NCT00648297</DOCNO>
	<brief_summary>The objective study investigate bioequivalence Mylan 's nadolol/bendroflumethiazide 80 mg/5 mg tablets King 's Corzide® 80 mg/5 mg tablet follow single , oral 80 mg/5 mg ( 1 x 80 mg/5 mg ) dose administer fed condition .</brief_summary>
	<brief_title>Fed Study Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg Corzide® Tablets 80 mg/5 mg</brief_title>
	<detailed_description />
	<mesh_term>Nadolol</mesh_term>
	<mesh_term>Bendroflumethiazide</mesh_term>
	<criteria>1 . Age : 18 year old 2 . Sex : Male and/or nonpregnant , nonlactating female 1 . Women childbearing potential must negative serum beta human chorionic gonadotropin ( βHCG ) pregnancy test perform within 21 day prior start study even prior dose administration . If dose schedule weekend , serum HCG pregnancy test collect within 48 hour prior dose study period . An additional serum ( βHCG ) pregnancy test perform upon completion study . 2 . Women childbearing potential must practice abstinence use acceptable form contraception throughout duration study . Acceptable form contraception include follow : 1. hormonal contraceptive take throughout study , 2. intrauterine device place least 3 month prior start study remain place study period , 3. barrier method contain use conjunction spermicidal agent , 4. surgical sterility ( tubal ligation , oophorectomy hysterectomy ) postmenopausal accompany document postmenopausal course least one year . 3 . Hormonal replacement therapy allow study . 4 . Women consider childbearing potential one follow report documented medical history : 1. postmenopausal absence menses least one ( 1 ) year , 2. bilateral oophorectomy without hysterectomy absence bleed least 6 month , 3. total hysterectomy 5 . During course study , study screen study exit , men woman childbearing potential must use spermicidecontaining barrier method contraception addition current contraceptive device . This requirement document informed consent form . 3 . Weight : At least 60 kg ( 132 lb . ) men 48 kg ( 106 lb . ) woman subject Body Mass Index ( BMI ) great equal 19 less equal 30 ( see Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS ) . 4 . All subject judge normal healthy prestudy medical evaluation ( physical examination , laboratory evaluation , 12lead ECG , hepatitis B hepatitis C test , HIV test , urine drug screen include amphetamine , benzodiazepine , cannabinoid , cocaine , opiate screen , phencyclidine , methadone ) perform within 21 day initial dose study medication . 1 . Institutionalized subject use . 2 . Social Habits : 1 . Use tobacco product within 1 year start study . 2 . Ingestion alcoholic , caffeine xanthinecontaining food beverage within 48 hour prior initial dose study medication . 3 . Ingestion vitamins herbal product within 7 day prior initial dose study medication . 4 . Any recent , significant change dietary exercise habit . 5 . Positive test drug include urine drug screen . 6 . History drug and/or alcohol abuse . 3 . Medications : 1 . Use prescription overthecounter ( OTC ) medication within 14 day prior initial dose study medication ( hormonal contraceptive hormone replacement therapy ) 2 . Use medication know alter hepatic enzyme activity within 28 day prior initial dose study medication . 4 . Diseases : 1 . History significant cardiovascular , hepatic , renal , pulmonary , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic disease . 2 . Acute illness time either prestudy medical evaluation dosing . 3 . A positive HIV , hepatitis B , hepatitis C test result . 4 . A history asthma , bronchiospasmic disease , chronic bronchitis , sinus bradycardia , great 1st degree conduction block . 5 . Abnormal clinically significant laboratory test result : 1 . Clinically significant deviation Guide Clinically Relevant Abnormalities ( See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS ) . 2 . Abnormal clinically relevant ECG tracing . 6 . Bradycardia le 50 beats/minute supine position , measure ECG , screen visit prior Period I Day 1 dosing . 7 . Sitting pulse rate le 60 beat per minute sit systolic blood pressure le 90 great 140 sit diastolic blood pressure le 60 great 90 fiveminute rest period Screening Visit prior Period I Day 1 dosing . 8 . Donation loss significant volume blood plasma ( &gt; 450 mL ) within 28 day prior initial dose study medication . 9 . Subjects receive investigational drug within 30 day prior initial dose study medication . 10 . Allergy hypersensitivity nadolol , propranolol , βadrenergic receptor blocker , bendroflumethiazide , sulfonamidederived drug , thiazide , related product . 11 . History difficulty swallow , gastrointestinal disease could affect drug absorption . 12 . Consumption grapefruit grapefruit containing product within 7 day drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>